CIS_DSC06188-2 NEWS ROOM arrow-down
News2021-09-29T13:08:44+02:00
712, 2018

CIS Pharma Christmas event in Bern

Bern, Switzerland, Friday, December 7, 2018 - For the end of year event, the team of CIS Pharma sets out to Bern, the capital of Switzerland. Our city guide Domenico Bernabei carries his heart and soul on his tongue and quickly catches our attention with city anecdotes of the last four centuries. His knowledge and entertainment skills got him featured [...]

2211, 2018

CIS Pharma starts collaboration with the Paul Scherer Institute on antibody-radionuclide conjugates

Bubendorf, Switzerland, Thursday, November 22, 2018 - CIS Pharma has identified the group of Prof. Schibli and Dr. Behe from the Paul Scherer Institute, ETH,  as potential partners for its antibody-radionuclide conjugate program. A scientific program for CIS Pharma’s synthesis unit was elaborated to develop by Q2/2019 novel polymer-drug carriers compatible with established conjugation technologies at Paul Scherer Institute. Upon [...]

111, 2018

Nordic Nanovectors presents promising Phase 1 study results on its antibody-radionuclide conjugate Betalutin

Philadelphia, USA, Thursday, November 1, 2018 - Betalutin is an antibody-radionuclide conjugate, ARC, representing a combination of lilotomab for targeting CD37, a protein that specifically exists on the surface of non-Hodgkin’s lymphoma cells, with the beta particle-emitting isotope lutetium-177. The radionuclide is immobilized with the help of a metal chelator. During treatment Betalutin is internalized into the cells and its [...]

1810, 2018

Novartis successfully completes acquisition of Endocyte and its new antibody-radionuclide conjugate

Zurich, Switzerland, Thursday, October 18, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment. With this Novartis can add the antibody-radionuclide conjugate 177-Lu-PSMA-617, a potential first-in-class therapy in Phase III development for metastatic castration-resistant prostate cancer to its portfolio. Novartis intends [...]

910, 2018

CIS Pharma team attends CPhI Worlwide 2018 in Madrid

Madrid, Spain, Tuesday to Thursday, October 9 to 11, 2018 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Madrid. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

1109, 2018

CIS Pharma summer event in Basel

Basel, Switzerland, Tuesday, September 11, 2018 - During our Summer Event we dive into the multifaceted side of Basel, Kleinbasel, at the northern banks of the river Rhine. Our trip starts with a ride on the Rhine taxi, taking us on a trip over the river, along the Cathedral Münster up to the Powerstation in Birsfelden and back down to [...]

3008, 2018

Approval received for innovative vial adaptor, available now for market introduction

Bubendorf, Switzerland, Friday, August 30, 2018 – CIS Pharma announces the approval of a vial adaptor specific for the preparation and injection of intracameral cefuroxime. Consequently, the adaptor was produced and is expected to reach the market shortly. The development is innovative device that prevents the 10mg/ml cefuroxime sodium solution from particulate contamination, containing several 5-micron filters. After reconstitution of [...]

2308, 2018

Antibody-drug conjugate market with an estimated CAGR of 19%

New York, USA, Thursday, August 23, 2018 - The advancement in the medical technology is driving the global market for antibody-drug conjugates. Preclinical research, the increasing research activities on antibody therapies, more research on advanced drug discoveries, increasing research on oncology diseases, the growing collaboration between research institutes, and the increasing number of biopharmaceuticals and biotechnology companies are acting as [...]

1007, 2018

CIS Pharma initiates a new R&D program on antibody-radionuclide conjugates

Bubendorf, Switzerland, Tuesday, July 10, 2018 - Over the course of the past months, CIS Pharma has developed concepts and strategies to conjugate  radioisotopes onto its polymer-drug carriers. First syntheses results and tests with cold substances are promising and CIS Pharma is proactively searching for scientific collaborations in the field of antibody-radionuclide conjugates, nuclear oncology respectively. [...]

2602, 2018

Intracameral cefuroxime launched in Europe

Bubendorf, Switzerland, Monday, February 26, 2018  - CIS Pharma’s licensee has launched intracameral cefuroxime across Europe. Among others, cataract clinics in France, Germany, Spain, Italy and Netherlands will be supplied with the product. The CIS Pharma team is proud that based on its development, thousands of patients are saved from going blind. CIS Pharma’s licensee has a strong market penetration [...]

702, 2018

CIS Pharma team attends Pharmapack 2018 in Paris

Paris, France, Wednesday to Thursday, February 7 to 8, 2018 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

2112, 2017

CIS Pharma has reached the first milestone in its SNI funded project

Bubendorf, Switzerland, Thursday, December 21, 2017 - CIS Pharma’s bio-membrane project has reached the first milestone. The polymer chemistry experts developed the a first prototype compatible with the 3D printing process. As key project milestones are achieved, the Swiss Nanoscience Institute will grant CIS Pharma a prolonged funding of its bio-membrane project: the cooperation with the University of Applied Sciences, [...]

812, 2017

CIS Pharma Christmas event at Palazzo Colombino

Basel, Switzerland, Friday, December 8, 2017 - We spend the night at Palazzo Colombino, a Variété that offers a night with delishes food and spectacular artistic performances. The exquisite dishes are created by the renowned chef of "Les Quatres Saisons", Peter Moser, each a feast for the eyes and culinary delight. What a spectacular evening, being taken into a world [...]

2410, 2017

CIS Pharma team attends CPhI Worlwide 2017 in Frankfurt

Frankfurt, Germany, Tuesday to Thursday, October 24 to 26, 2017 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Frankfurt. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

1610, 2017

CIS Pharma verified compatibility of its polymer-drug carriers to be used in antibody-drug conjugates and antibody-radionuclid conjugates

Bubendorf, Switzerland, Monday, October 16, 2017 - The polymer experts from CIS Pharma successfully accomplished a first proof-of-concept study on the compatibility of their polymer-drug carriers with a conjugation technique of NBE Therapeutics. The polymer-drug carrier loaded with tracer molecules was enzymatically conjugated to a model antibody and the ADC subsequently analyzed for its affinity to bind the target. In [...]

2007, 2017

CIS Pharma summer event in Alsace

Strasbourg, France, Thursday, July 20, 2017 - The CIS Pharma Summer Event takes us to Alsace, France. Our first stop is well known in France and abroad for its foie gras, the farm of Lucien Doriath in Soulz-les-Bains. At the in-house restaurant, we indulge in delicacies. Our next stop is at the Domaine Agapé in Riquewihr on the Alsace Route [...]

2906, 2017

Besponsa, a new antibody-drug conjugate, ADC, approved in the EU

London, GB, Thursday, June 29, 2017 - The ADC Besponsa - inotuzumab ozogamicin, Pfizer Inc. - is a cancer medicine used to treat a type of blood cancer which affects B cells called “B-cell precursor acute lymphoblastic leukaemia”. Besponsa is used on its own in adults whose cancer has come back or did not respond to previous treatment. It is [...]

405, 2017

CIS Pharma presenting ADC drug carrier technology at Swiss Biotech Day 2017

Basel, Switzerland, Thursday, May 4, 2017 - CIS Pharma presents its ADC drug carrier technology at Swiss Biotech Day 2017, scheduled for 14:10 during the Emerging Companies Streams. CIS Pharma ADC drug carriers are based on the proprietary Cellophil® Smart Polymer technology that allows the ADCs to be custom designed for delivery of a wide array of anti-tumor agents directly [...]

2604, 2017

CIS Pharma starts R&D project by SNI for 3D printed biocompatible membranes for tissue regeneration

Bubendorf, Switzerland, Wednesday, April 26, 2017 - The Swiss Nanoscience Institute has granted CIS Pharma funding for an innovative project in the field of implantology. The Project is a collaboration between the University of Applied Science, FHNW in Muttenz and the High-tech Research Center in Basel. During this project a biocompatible membrane is developed to enhance tissue regeneration at the [...]

102, 2017

CIS Pharma team attends Pharmapack 2017 in Paris

Paris, France, Wednesday to Thursday, February 1 to 2, 2017 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

112, 2016

CIS Pharma appoints Dr. Christophe Thommen as new head of research and laboratory operations

Bubendorf, Switzerland, Thursday, December 1, 2016 - CIS Pharma welcomes Dr. Christophe Thommen, who will lead the research team as the new head of research and laboratory operations. Christophe is an expert in natural products chemistry and his expertise has already led to a number of innovative and efficient syntheses in the industry. With his focus on scalability and industrialization [...]

2110, 2016

CIS Pharma’s solubilization technology comprising cyclosporine A has entered proof of concept phase

Bubendorf, Switzerland, Friday, October 21, 2016 - CIS Pharma’s novel solubilization strategy for hydrophobic drugs has successfully reached the proof of concept phase. The Cellophil® Smart Polymer technology platform creates water-soluble formulations for a number of model drugs such as cyclosporine A. The technology can be applied to a large number of water-insoluble drugs, improving the bioavailability and tolerance for [...]

410, 2016

CIS Pharma team attends CPhI Worlwide 2016 in Barcelona

Barcelona, Spain, Tuesday to Thursday, October 4 to 6, 2016 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Barcelona. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

509, 2016

CIS Pharma has successfully concluded the development of novel contact lens coating technology

Bubendorf, Switzerland, Monday, September 5, 2016 - CIS Pharma has concluded the development of a novel contact lens coating technology based on the Cellophil® Smart Polymer platform. The technology has been shown to increase surface wettability and lubricity and is expected to increase the wear comfort of silicone hydrogel contact lenses. CIS Pharma has created novel bio-inspired polymer derivatives based [...]

Nach oben